$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How long does it take to take giritinib?
2026-02-01 22:25:32
Check Details
How long does it take for gilitinib to take effect?
2026-02-01 22:25:32
Check Details
giritinib price in india
2026-02-01 22:25:32
Check Details
There are several versions of generic versions of giritinib
2026-02-01 22:25:32
Check Details
Whether giritinib is effective or not has been announced in China
2026-02-01 22:25:32
Check Details
Is it true that giritinib has a 70% clearance rate for FLT3 gene mutations?
2026-02-01 22:25:32
Check Details
Detailed explanation of how much does giritinib cost?
2026-02-01 22:25:32
Check Details
Is it true that the targeted drug giritinib is given away?
2026-02-01 22:25:32
Check Details
Can the targeted drug giritinib cure leukemia with genetic mutations?
2026-02-01 22:25:32
Check Details
Gilteritinib maintenance therapy shows benefit in MRD+FLT 3-mutant AML after HCT
2026-02-01 22:25:32
Check Details
Effect of Lorlatinib on brain metastasis
2026-02-01 22:25:32
Check Details
What should I do if I become resistant to Lorlatinib?
2026-02-01 22:25:32
Check Details
1
2
...
425
426
427
428
429
430
431
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
2
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
3
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
4
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
5
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
6
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
7
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
8
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
9
Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia
10
Ponatinib vs. Olverembatinib: A Multidimensional Comparison of Third-Generation BCR-ABL Inhibitors
11
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
12
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)